Tesaro Wins FDA Approval for Ovarian Cancer Drug Zejula

Tesaro Inc TSRO recently announced that the FDA has approved its oral once daily poly ADP ribose polymerase PARP inhibitor Zejula niraparib for the maintenance treatment of women suffering from recurrent epithelial ovarian fallopian tube or primary peritoneal cancer who are in